Furiex Pharmaceuticals, Inc. Confirms Takeda Will Present Additional Data From The EXAMINE Trial At American College of Cardiology’s 63rd Annual Scientific Session

Published: Mar 27, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that its partner Takeda Pharmaceuticals Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology’s (ACC) 63rd Annual Scientific Session in Washington, DC. These sub-analyses specifically relate to the effects of alogliptin on rates of CV mortality and hospitalization for heart failure (HF).

Help employers find you! Check out all the jobs and post your resume.

Back to news